Co-Authors
This is a "connection" page, showing publications co-authored by MICHAEL LEWIS and THOMAS WESTBROOK.
Connection Strength
0.451
-
Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer. Nat Med. 2018 05; 24(4):505-511.
Score: 0.164
-
Selective small molecule Stat3 inhibitor reduces breast cancer tumor-initiating cells and improves recurrence free survival in a human-xenograft model. PLoS One. 2012; 7(8):e30207.
Score: 0.111
-
Tumor suppressor PLK2 may serve as a biomarker in triple-negative breast cancer for improved response to PLK1 therapeutics. Cancer Res Commun. 2021 12; 1(3):178-193.
Score: 0.053
-
Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancer. Cell. 2021 01 21; 184(2):384-403.e21.
Score: 0.050
-
Erratum: Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation. Nat Cell Biol. 2016 06 28; 18(7):822.
Score: 0.036
-
Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation. Nat Cell Biol. 2016 06; 18(6):632-44.
Score: 0.036